Cellectar Biosciences, Inc.
CLRB
$2.37
-$0.05-1.87%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -22.58% | -6.77% | -19.16% | 18.43% | 17.51% |
| Total Depreciation and Amortization | 132.27% | -322.22% | -5.35% | -5.94% | -1.24% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -6.94% | 28.09% | -0.96% | 255.03% | -91.04% |
| Change in Net Operating Assets | -1.39% | -10.58% | 446.66% | -190.74% | 105.18% |
| Cash from Operations | -24.03% | -11.54% | -1.61% | 16.43% | 45.48% |
| Capital Expenditure | 100.00% | 42.37% | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 100.00% | 42.37% | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -13.76% | 157.10% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | -- | -13.76% | 157.10% | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 628.92% | -855.63% | -57.60% | 152.84% | 69.48% |